Members of the Pharmaceutical Society of South Africa are in favor of a new cost structure that will reduce the prices of medicines, PSSA president Cecil Abrahamson has told the National Assembly's select committee on health.
he said it was wrong to blame pharmacists for high medicine prices, noting that they agree that drug prices are too high, and they want to be part of the solution. This is why the Society is working on a plan in conjunction with manufacturers and wholesalers. The Society represents 57% of South Africa's 10,000 pharmacists, who are an integral part of the country's health care system and must be accessible to the nation, he said. To this end, plans are underway to introduce mobile pharmacies into less accessible areas.
PSSA executive director Ivan Kotze told the committee that the Society was concerned that it had not been consulted on proposed legislation to restructure the South African Pharmaceutical Council, which regulates the profession. Concerning the new cost structure, which is to be implemented as soon as possible, mr Kotze told the Marketletter that the Society was investigating a net-pricing system, regulated distribution costs and a professional fee per prescription (not item), instead of the current market-up and discount system. This could influence medicine prices "significantly," he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze